PharMerica Beats Analyst Estimates on EPS
PharMerica (NYS: PMC) reported earnings on Nov. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), PharMerica met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share grew significantly.
Gross margins increased, operating margins dropped, net margins grew.
PharMerica reported revenue of $442.0 million. The eight analysts polled by S&P Capital IQ predicted a top line of $446.4 million on the same basis. GAAP reported sales were 15% lower than the prior-year quarter's $518.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.33. The nine earnings estimates compiled by S&P Capital IQ predicted $0.30 per share. GAAP EPS of $0.20 for Q3 were 25% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.1%, 270 basis points better than the prior-year quarter. Operating margin was 2.8%, 60 basis points worse than the prior-year quarter. Net margin was 1.4%, 50 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $434.9 million. On the bottom line, the average EPS estimate is $0.30.
Next year's average estimate for revenue is $1.84 billion. The average EPS estimate is $1.22.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 122 members out of 127 rating the stock outperform, and five members rating it underperform. Among 20 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give PharMerica a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $14.79.
- Add PharMerica to My Watchlist.
The article PharMerica Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.